TD Cowen Upgrades Ocular Therapeutix to Buy, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Tara Bancroft has upgraded Ocular Therapeutix (NASDAQ:OCUL) from Hold to Buy and raised the price target from $7 to $11.
June 20, 2024 | 9:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Tara Bancroft has upgraded Ocular Therapeutix from Hold to Buy and raised the price target from $7 to $11.
The upgrade from Hold to Buy and the significant increase in the price target from $7 to $11 by a reputable analyst is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100